Exciva is a technology company.
Exciva has raised $10.0M across 1 funding round.
Exciva has raised $10.0M in total across 1 funding round.
Exciva GmbH is a German biotechnology company developing therapies for neuropsychiatric symptoms in Alzheimer's disease, particularly agitation and aggression.[1][2] It pursues a targeted drug rescue program, repurposing existing compounds through rigorous clinical trials to deliver first-in-class treatments that improve patient quality of life, reduce caregiver burden, and transform dementia care.[1][2] The company serves Alzheimer's patients experiencing these symptoms, their caregivers, and families, addressing a major unmet need in neuropsychiatry.[1][2] With over $10 million in funding, including a €9 million Series A led by Andera Partners, Exciva has 6 employees and shows clinical momentum, advancing its lead candidate toward Phase II trials.[1][3]
Exciva GmbH was founded in 2015 (with some sources noting 2016) in Heidelberg, Germany, as a privately held biotech firm.[1][2][4] François Conquet serves as CEO, leading a team with deep expertise in central nervous system (CNS) research and pharmaceutical development from prior industry roles.[3] The idea emerged from identifying unmet needs in Alzheimer's behavioral symptoms, leveraging a drug rescue approach that combines compounds with proven safety and efficacy profiles.[1][3] Early traction came via support from Andera Partners since inception, culminating in the 2021 Series A round with LBBW Venture Capital and Cure 8, enabling Phase I completion and Phase II initiation.[3]
Exciva rides the wave of neuropsychiatry innovation in aging populations, targeting behavioral symptoms in Alzheimer's—a market with massive unmet needs amid rising dementia prevalence.[2][3] Timing aligns with advances in drug repurposing, which cuts costs and speeds timelines in biotech, especially post-pandemic emphasis on efficient CNS therapies.[1][3] Favorable forces include growing investor interest in Alzheimer's (e.g., Andera's medtech focus) and regulatory pushes for symptom-specific treatments.[3] Exciva influences the ecosystem by validating repurposed combos, potentially lowering barriers for similar CNS startups and shifting dementia care from symptom management to targeted relief.[2]
Exciva's path forward centers on Phase II trial success for its lead candidate, potentially yielding proof-of-concept data that de-risks partnerships or further funding.[3] Trends like AI-driven drug discovery and personalized neuropsychiatry will amplify its repurposing edge, while an aging global population sustains demand.[2] Its influence may grow through licensing deals or acquisitions by big pharma seeking Alzheimer's pipelines, solidifying Exciva as a key player in biotech's fight against dementia's hidden burdens—echoing its mission to restore patient dignity from day one.[2]
Exciva has raised $10.0M in total across 1 funding round.
Exciva's investors include Andera Partners, Karista, Wellington Partners.
Exciva has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in October 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2021 | $10.0M Series A | Andera Partners, Karista, Wellington Partners |